Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Current Deferred Revenue (2016 - 2025)

Standard Biotools (LAB) has disclosed Current Deferred Revenue for 16 consecutive years, with $40.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 13.03% to $40.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $40.1 million, a 13.03% decrease, with the full-year FY2024 number at $10.3 million, down 32.08% from a year prior.
  • Current Deferred Revenue was $40.1 million for Q3 2025 at Standard Biotools, down from $43.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $47.8 million in Q1 2024 to a low of $10.3 million in Q4 2024.
  • A 5-year average of $21.9 million and a median of $15.1 million in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 690.11% in 2021, then plummeted 40.1% in 2022.
  • Standard Biotools' Current Deferred Revenue stood at $17.9 million in 2021, then decreased by 18.45% to $14.6 million in 2022, then increased by 3.55% to $15.1 million in 2023, then tumbled by 32.08% to $10.3 million in 2024, then skyrocketed by 290.41% to $40.1 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Current Deferred Revenue are $40.1 million (Q3 2025), $43.0 million (Q2 2025), and $45.3 million (Q1 2025).